(g) whetheir it is also a fact that these compaines are manufacturing certain Vitamins and Tonics without any industrial licence which are products of douhtful validity; if so, the names of these products; and

(h) whether it is a fact that there are a number of substitutes of these products available and if so, their names,

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (d) M/s. Burroughs WeUcome, M/s. Glaxo Laboratories India Limited, M/s. Pfizer Limited have been issued prima facie Show Cause notices for contravening the provisions of Section 13(1) (d) of the Industries (Development & Regulation) Act, 1951. These companies have submitted representations which are being looked into.

(e) and (f) Instances of such contravention in respect of the following companies have come to the notice of the Government:—

1. M/s. Bayer India Limited
2. M/s. S. G. Pharmaceuticals S.
M/s. Sarabhai M. Chemicals
4. M/s. Synbiotics Limited
5. M/s. Cynamid India Limited
6. M/s. Alembic Chemicals Limited
7. M/s. Hoechst Pharmaceuticals Limited
8. M/s. Abbott Laboratories Limited
9. M|s. Astra IDL Limited
10. M/s. Fairdeai Corporation of India Limited

1. M/s. Bayer India Limited
2. M/s. S. G. Pharmaceuticals S. M/s.
Sarabhai M. Chemicals
4. M/s. Synbiotics Limited
5. M/s. Cynamid India Limited
6. M/s. Alembic Chemicals Limited
7. M/s. Hoechst Pharmaceuticals Limited
8. M/s. Abbott Laboratories Limited
9. M|s. Astra IDL Limited

10. M/s. Fairdeai Corporation of India LimitedThe Technical Team has conducted on the spot verification of the above companies and has since submitted its reports. In *3* cases namely, M/s. Synbiotics Limited M|s. Alembic Chemi- | cals Limited and M/s. Fairdeai' Cor- *I.* poration of India Limited, final view was taken that there was no case of infraction of Industries (Develpoment & Regulation) Act. Final views on the reports in respect of the remaining cases are yet to be taken.

(g) The requisite information is being collected and will be laid on the Table fo the House.

(h) Details of substitutes are not available.

Drue equalisation fund account dues

.22173. DR. JOSEPH LEON D'SOUZA: Will the minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Starred Question 91 given in the Rajya Safoha on the 29th July, 1985 and state;

(a) whether it is a fact that crores of Rupees is due to the exchequer under drug_ equalisaion fund account only during the period 1983-84 on account of unintended benefit du_e to the price difference between the purchase and realised prices on phenoberbitone, Ibuprofen. Ephedine HCL, Trimethoprim, Sulphamet-hexazole, Furose-mide, Pyrental Paomate, Prednisolone, Pseudo Ephedne. Dextrose Ashy-drous, Isopropyl/Antipyrina and Gen-tamcin Sulphate;

(b) whether it a fact that claims worked out to around Rupees thirty lacs on Phenobarbitone, seventy three lacs on Ibuprofen, and fifty four lacs on Ephedrine Hcl;

(c) what is the amount du_e to Government under drug equalisation fund account on each drug during 1983-84 i only along with the names of the parties; and what are the reasons for not collecting the same?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (d) $Name_s$ of the companies and the bulk drugs for which they were issued notices for recovery into the Drug Prices Equalisation Account havo already been indicated in reply to Rajya Sabha

Unstarred Question No. 1844 answered on 12-8-1985. Whenever any instance of the bulk drug having been produced at a price less than the price allowed in the formulationa comes into the notice of the Government, notices are issued to recover the difference in the Drug Prices Equalisation Account under Paragraph 7 of the Drug (Prices Control) Order, 1979. The process of recovery is on in accordance with due procedure of law. One of the masufacturer, namely M|s. Fulford India Ltd. have filed a Writ Petition in the Delhi High Court against the notice of recovery. The Writ Petition is yet to be admitted and the matter is now listed for hearing on 9th September, 1985.

Production of antiseptic drugs

2274. DR. JOSPH LEON D'SOUZA: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 801 given in the Rajya Sa-bha on the 21st November, 1983 and state:

(a) whether it ig a fact that Fair-deal Corporation and Astra-IDL did not include antiseptic preparations Itiol and Fairgenol in their applica-tiona submitted for permission under KD&R) Act;

(b) if so, how the companies claimed approvals in the absence of specific mention of these items;

(c) whether Government have received explanations from them;

(d) if so, what are the main grounds of justification and what action was taken for violation of the rules/law;

(e) whether the investigation about the supply of these antiseptics to Government at much higher price than approved have been completed;

(t) if so, what is the outcome and what action was taken;

(g) whether it is a fact that these companies are marketing number of medicines without price approval;

(h) whether any verification was done; if so, the details thereof; and

(i) what are the names of the formulations marketed by the Companies and their approved and selling prices?

THE MINISTER OF CHEMICALS AND FERTILIZERS' (SHRI VEERENDRA PATIL): (a) to (i) The information is being collected and will be laid on the table of the House.

Manufacture of Bulk Drug by Multinationals

2275. DR. JOSEPH LEON D'SOUZA; Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state;

(a) whether it is a fact that M/s. Abbott and Pfizer are not manufacturing bulk drugs in regard to which the Delhi High Court quashed the price fixation order; issued by his Ministry;

(b) if so, what were the grounds for quashing the order;

(o) whether it is a fact that all the formulations are vitamin preparations;

(d) what is the composition and indication of each product;

(e) what was the sales turnover of each product during the last three years, year-wise, and what percentage the same bore to the total sales turnover;

(f) what was their total gales turnover, pre-tax profit net worth capital employed, ex-factory value of production of bulk drugs and formulations during the last three years, year-wise;

(g) whether it is a fact that these companies have overproduced vitamin preparations than their licensed capacity by installing unauthorised plant and machinery; and

((h) if so, what was their licensed capacity and production of each item taken into account while applying for reendorsement?